Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

CagrilintideExplore study findings

Why the four arms of REDEFINE 1 mattered for cagrilintide

3 numbered sourcesSource years 2025, 2026

Peptides are short chains whose amino acids are linked by peptide bonds. Some work by activating receptors that sense signals from the gut or pancreas. Cagrilintide is an investigational long-acting amylin-based peptide. The older primary REDEFINE 1 report matters for the specific question of cagrilintide alone because the large weight-management trial included a separate cagrilintide arm alongside the fixed combination. [1]

The study randomized 3,417 adults with overweight and a related complication or with obesity. They did not have diabetes. The participants were assigned to the combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo. Lifestyle support was part of all four groups. A four-arm design lets investigators ask how much weight changed with each assigned intervention and how the combination compares with its individual components in the same population. [1]

The main statistical tests compared the combination with placebo. At 68 weeks, the mean estimated weight change was −20.4% with the combination and −3.0% with placebo under an analysis intended to reflect treatment assignment regardless of whether participants stayed on the assigned intervention. The separate cagrilintide arm included 302 people, compared with 2,108 in the combination arm. That difference in group size matters because a group with fewer participants generally yields less precise estimates, all else being equal. It also reflects the study’s primary focus on the combination. [1]

Two outcomes were designated primary. One measured average percentage weight change and the other asked how many people reached at least a 5% reduction. An average can move substantially even when responses vary across the group. A threshold tells the reader something about how frequently people reached a specified result. Looking at both types of outcome gives a fuller account of the weight response than either measure by itself. [1]

The cagrilintide-only arm is direct human evidence about a defined preparation and population, while the 20.4% estimate belongs to the tested pair. Applying it to cagrilintide alone would assign a result to a different intervention. The older primary paper also supplies the context for later analyses of participants’ blood pressure and other measures. Those papers can extend the set of outcomes reported from REDEFINE 1. Because they use the same participants, they do not constitute independent replications of the main weight result. New monotherapy trials can add independent evidence when they report outcomes. Their registry plans identify separate placebo comparisons in people with and without type 2 diabetes. [1, 2, 3]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Cagrilintide

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.